ATE458735T1 - Pyridino[1,2-a pyrimidin-4-onverbindungen als mittel gegen krebs - Google Patents
Pyridino[1,2-a pyrimidin-4-onverbindungen als mittel gegen krebsInfo
- Publication number
- ATE458735T1 ATE458735T1 AT04776639T AT04776639T ATE458735T1 AT E458735 T1 ATE458735 T1 AT E458735T1 AT 04776639 T AT04776639 T AT 04776639T AT 04776639 T AT04776639 T AT 04776639T AT E458735 T1 ATE458735 T1 AT E458735T1
- Authority
- AT
- Austria
- Prior art keywords
- pyridino
- compounds
- pyrimidine
- cancer agent
- alone
- Prior art date
Links
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical class O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 title 1
- 239000002246 antineoplastic agent Substances 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 2
- -1 pyridino[1,2-a]pyrimidinyl compounds Chemical class 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48018003P | 2003-06-20 | 2003-06-20 | |
| PCT/US2004/019158 WO2004113335A2 (en) | 2003-06-20 | 2004-06-17 | Pyridino[1,2-a]pyrimidin-4-one compounds as anticancer agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE458735T1 true ATE458735T1 (de) | 2010-03-15 |
Family
ID=33539266
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04776639T ATE458735T1 (de) | 2003-06-20 | 2004-06-17 | Pyridino[1,2-a pyrimidin-4-onverbindungen als mittel gegen krebs |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7326711B2 (de) |
| EP (1) | EP1636225B1 (de) |
| JP (1) | JP2007520435A (de) |
| KR (1) | KR20060069356A (de) |
| CN (1) | CN1809563A (de) |
| AT (1) | ATE458735T1 (de) |
| AU (1) | AU2004249730A1 (de) |
| CA (1) | CA2528771A1 (de) |
| DE (1) | DE602004025698D1 (de) |
| ES (1) | ES2339862T3 (de) |
| IL (1) | IL172192A0 (de) |
| MX (1) | MXPA05013142A (de) |
| PT (1) | PT1636225E (de) |
| TW (1) | TW200503719A (de) |
| WO (1) | WO2004113335A2 (de) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ526622A (en) * | 2000-12-11 | 2006-07-28 | Amgen Sf Llc | CXCR3 antagonists |
| US6794379B2 (en) | 2001-06-06 | 2004-09-21 | Tularik Inc. | CXCR3 antagonists |
| PT1601673E (pt) * | 2003-03-07 | 2009-07-29 | Astrazeneca Ab | Heterociclos fundidos e suas utilizações |
| AR050920A1 (es) * | 2003-03-07 | 2006-12-06 | Astrazeneca Ab | Enantiomeros de heterociclos fusionados seleccionados y usos de los mismos |
| US7572914B2 (en) * | 2003-12-19 | 2009-08-11 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| WO2005082343A2 (en) * | 2004-02-25 | 2005-09-09 | La Jolla Pharmaceutical Company | Amines and amides for the treatment of diseases |
| ATE419249T1 (de) * | 2004-04-06 | 2009-01-15 | Novartis Vaccines & Diagnostic | Inhibitoren von mitotischem kinesin |
| WO2005105788A1 (en) * | 2004-04-23 | 2005-11-10 | Takeda San Diego, Inc. | Indole derivatives and use thereof as kinase inhibitors |
| US20070287703A1 (en) * | 2004-07-22 | 2007-12-13 | Astrazeneca Ab | Fused Pyrimidones Useful in the Treatment and the Prevention of Cancer |
| WO2006023931A2 (en) * | 2004-08-18 | 2006-03-02 | Takeda San Diego, Inc. | Kinase inhibitors |
| CN101027309B (zh) | 2004-08-18 | 2010-10-27 | 阿斯利康(瑞典)有限公司 | 所选择的稠合嘧啶酮的对映体和在治疗和预防癌症中的用途 |
| US20060041128A1 (en) * | 2004-08-18 | 2006-02-23 | Astrazeneca Ab | Selected fused heterocyclics and uses thereof |
| EP1812439B2 (de) | 2004-10-15 | 2017-12-06 | Takeda Pharmaceutical Company Limited | Kinaseinhibitoren |
| GB0428250D0 (en) * | 2004-12-23 | 2005-01-26 | Novartis Ag | Organic compounds |
| US20070027150A1 (en) * | 2005-04-14 | 2007-02-01 | Bellamacina Cornelia R | 2-Amino-quinazolin-5-ones |
| DE602006015658D1 (de) | 2005-06-27 | 2010-09-02 | Amgen Inc | Entzündungshemmende arylnitrilverbindungen |
| US8119655B2 (en) * | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| EP2223925A1 (de) * | 2006-10-09 | 2010-09-01 | Takeda Pharmaceutical Company Limited | Kinase-Inhibitoren |
| JP2010505962A (ja) | 2006-10-09 | 2010-02-25 | 武田薬品工業株式会社 | キナーゼ阻害剤 |
| GEP20125415B (en) | 2007-01-05 | 2012-03-12 | Novartis Ag | Imidazole derivatives as kinesin spindle protein inhibitors (eg-5) |
| EP2448938B9 (de) | 2009-06-29 | 2015-06-10 | Incyte Corporation | Pyrimidinone als pi3k-hemmer |
| WO2011075643A1 (en) | 2009-12-18 | 2011-06-23 | Incyte Corporation | Substituted heteroaryl fused derivatives as pi3k inhibitors |
| EP2558463A1 (de) | 2010-04-14 | 2013-02-20 | Incyte Corporation | Kondensierte derivate als i3-hemmer |
| US9062055B2 (en) | 2010-06-21 | 2015-06-23 | Incyte Corporation | Fused pyrrole derivatives as PI3K inhibitors |
| JP5961187B2 (ja) | 2010-12-20 | 2016-08-02 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｐｉ３ｋ阻害剤としてのｎ−（１−（置換フェニル）エチル）−９ｈ−プリン−６−アミン |
| US9108984B2 (en) | 2011-03-14 | 2015-08-18 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors |
| US9126948B2 (en) | 2011-03-25 | 2015-09-08 | Incyte Holdings Corporation | Pyrimidine-4,6-diamine derivatives as PI3K inhibitors |
| MX389479B (es) | 2011-09-02 | 2025-03-20 | Incyte Holdings Corp | Heterociclilaminas como inhibidores de fosfoinositida 3-cinasas (pi3k) |
| EP3406252B1 (de) | 2012-02-10 | 2020-05-13 | PTC Therapeutics, Inc. | Verbindungen zur behandlung von spinaler muskelatrophie |
| US9371336B2 (en) | 2012-03-01 | 2016-06-21 | Ptc Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| EP2828247B1 (de) | 2012-03-23 | 2019-01-16 | PTC Therapeutics, Inc. | 4h-chromen-4-onderivate zur behandlung von spinaler muskelatrophie |
| AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
| WO2015105657A1 (en) | 2013-12-19 | 2015-07-16 | Ptc Therapeutics, Inc. | Methods for modulating the amount of rna transcripts |
| US10077277B2 (en) | 2014-06-11 | 2018-09-18 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors |
| SG10201912302VA (en) | 2015-02-27 | 2020-02-27 | Incyte Corp | Salts of pi3k inhibitor and processes for their preparation |
| PE20180316A1 (es) * | 2015-04-15 | 2018-02-09 | Hoffmann La Roche | Compuestos piridopirimidinona y su uso como moduladores del receptor de nmda |
| US10441570B2 (en) | 2015-04-21 | 2019-10-15 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (SARD) Ligands and methods of use thereof |
| US9988401B2 (en) | 2015-05-11 | 2018-06-05 | Incyte Corporation | Crystalline forms of a PI3K inhibitor |
| WO2016183060A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
| EP3298017B1 (de) * | 2015-05-20 | 2019-08-14 | H. Hoffnabb-La Roche Ag | Verbindungen zur behandlung von spinaler muskelatrophie |
| EP3310169B1 (de) | 2015-05-30 | 2023-05-17 | PTC Therapeutics, Inc. | Verfahren zur modulation von rna-spleissen |
| CA3119019C (en) | 2015-12-10 | 2024-06-11 | Ptc Therapeutics, Inc. | Compounds and methods for treating huntington's disease |
| JP2019535789A (ja) | 2016-11-28 | 2019-12-12 | ピーティーシー セラピューティクス，インコーポレーテッド | Ｒｎａスプライシングを調節する方法 |
| EP4151627A1 (de) | 2017-06-05 | 2023-03-22 | PTC Therapeutics, Inc. | Verbindungen zur behandlung von morbus huntington |
| CN111372611A (zh) | 2017-06-14 | 2020-07-03 | Ptc医疗公司 | 修饰rna剪接的方法 |
| CN111182898B (zh) | 2017-06-28 | 2024-04-16 | Ptc医疗公司 | 用于治疗亨廷顿氏病的方法 |
| CN111163838B (zh) | 2017-06-28 | 2023-03-28 | Ptc医疗公司 | 用于治疗亨廷顿氏病的方法 |
| CN108191860B (zh) * | 2018-02-12 | 2019-12-10 | 中国医科大学 | 一种HIF-2α小分子抑制剂及其用途 |
| BR112020019373A2 (pt) | 2018-03-27 | 2020-12-29 | Ptc Therapeutics, Inc. | Compostos para o tratamento da doença de hutington |
| IL278889B2 (en) | 2018-06-01 | 2025-11-01 | Incyte Corp | Dosing regimen for the treatment of pi3k related disorders |
| IL279688B2 (en) | 2018-06-27 | 2025-01-01 | Ptc Therapeutics Inc | Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease |
| WO2020005882A1 (en) | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| KR20210038845A (ko) | 2018-06-27 | 2021-04-08 | 피티씨 테라퓨틱스, 인크. | 헌팅턴병 치료를 위한 헤테로아릴 화합물 |
| CA3139821A1 (en) | 2019-05-13 | 2020-11-19 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3639593B2 (ja) * | 1993-05-31 | 2005-04-20 | 科研製薬株式会社 | 塩基性線維芽細胞増殖因子含有架橋ゼラチンゲル製剤 |
| GB2307177A (en) | 1995-11-15 | 1997-05-21 | Agrevo Uk Ltd | Fungicidal pyridopyrimidines |
| EP1226129B1 (de) | 1999-10-27 | 2006-05-24 | Cytokinetics, Inc. | Chinazolinone benutzende verfahren und zusammenstellungen |
| US6545004B1 (en) * | 1999-10-27 | 2003-04-08 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
| NZ526622A (en) | 2000-12-11 | 2006-07-28 | Amgen Sf Llc | CXCR3 antagonists |
| EP1379554A2 (de) * | 2001-02-21 | 2004-01-14 | Curagen Corporation | Proteine, dafür codierende polynukleotide und methoden unter verwendung davon |
| CA2465491A1 (en) * | 2001-11-07 | 2003-05-15 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| WO2003050122A2 (en) | 2001-12-06 | 2003-06-19 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| JP4467979B2 (ja) | 2001-12-06 | 2010-05-26 | メルク・シャープ・エンド・ドーム・コーポレイション | 有糸分裂キネシン阻害剤 |
| JP2006515886A (ja) * | 2003-01-17 | 2006-06-08 | サイトキネティクス・インコーポレーテッド | 化合物、組成物、および方法 |
-
2004
- 2004-06-17 ES ES04776639T patent/ES2339862T3/es not_active Expired - Lifetime
- 2004-06-17 KR KR1020057024411A patent/KR20060069356A/ko not_active Ceased
- 2004-06-17 JP JP2006517308A patent/JP2007520435A/ja active Pending
- 2004-06-17 DE DE602004025698T patent/DE602004025698D1/de not_active Expired - Lifetime
- 2004-06-17 EP EP04776639A patent/EP1636225B1/de not_active Expired - Lifetime
- 2004-06-17 CA CA002528771A patent/CA2528771A1/en not_active Abandoned
- 2004-06-17 CN CNA2004800171391A patent/CN1809563A/zh active Pending
- 2004-06-17 US US10/870,707 patent/US7326711B2/en not_active Expired - Fee Related
- 2004-06-17 PT PT04776639T patent/PT1636225E/pt unknown
- 2004-06-17 WO PCT/US2004/019158 patent/WO2004113335A2/en not_active Ceased
- 2004-06-17 AU AU2004249730A patent/AU2004249730A1/en not_active Abandoned
- 2004-06-17 MX MXPA05013142A patent/MXPA05013142A/es active IP Right Grant
- 2004-06-17 AT AT04776639T patent/ATE458735T1/de not_active IP Right Cessation
- 2004-06-18 TW TW093117650A patent/TW200503719A/zh unknown
-
2005
- 2005-11-24 IL IL172192A patent/IL172192A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1809563A (zh) | 2006-07-26 |
| WO2004113335A3 (en) | 2005-03-24 |
| PT1636225E (pt) | 2010-05-03 |
| WO2004113335A2 (en) | 2004-12-29 |
| TW200503719A (en) | 2005-02-01 |
| JP2007520435A (ja) | 2007-07-26 |
| MXPA05013142A (es) | 2006-03-17 |
| DE602004025698D1 (de) | 2010-04-08 |
| KR20060069356A (ko) | 2006-06-21 |
| EP1636225A2 (de) | 2006-03-22 |
| CA2528771A1 (en) | 2004-12-29 |
| US7326711B2 (en) | 2008-02-05 |
| IL172192A0 (en) | 2006-04-10 |
| AU2004249730A1 (en) | 2004-12-29 |
| EP1636225B1 (de) | 2010-02-24 |
| US20050085490A1 (en) | 2005-04-21 |
| ES2339862T3 (es) | 2010-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602004025698D1 (de) | PYRIDINOi1,2-A PYRIMIDIN-4-ONVERBINDUNGEN ALS MITTEL GEGEN KREBS | |
| ATE538103T1 (de) | Chinazolinonverbindungen als antikrebsmittel | |
| WO2005070930A3 (en) | Tetrahydrocarboline compounds as anticancer agents | |
| TW200505454A (en) | Heteroaryl-fused pyrimidinyl compounds as anticancer agents | |
| TNSN08143A1 (en) | 2-amino-7,8-dihydro-6h-pyrido[4,3-d]pyrimidin-5-ones | |
| BRPI0510560A (pt) | pirido[2,3-d] pirimidin-7-onas pirrolil substituìdas e seus derivados como agentes terapêuticos | |
| WO2004006859A3 (en) | Platinum compound | |
| MY148583A (en) | Pyridine [3,4-b] pyrazinones | |
| FR13C0062I1 (de) | ||
| CA2603830A1 (en) | PYRIDINE [2,3-B] PYRAZINONES | |
| IL175716A (en) | 2- (4-Bromo- or 4-Methyl-Phenylamino) -6-Oxo-1,6-Dihydropyridines and their use in drug preparation | |
| PL377821A1 (pl) | 2,4,6-tripodstawione pirymidyny jako inhibitory kinazy fosfatydyloinozytolu (PI) 3 i ich zastosowanie w leczeniu nowotworu | |
| IS7857A (is) | Setnar pýrróló-pýrasól afleiður sem kínasa hindrar | |
| WO2009143156A3 (en) | Imidazo [1, 2-a] pyridine compounds as gaba-a receptor modulators | |
| WO2006130607A3 (en) | Controlled-release formulation useful for treating disorders associated with hepatitis c virus | |
| NO20063231L (no) | Pyrido[2,3-D]pyrimidin-2,4-diaminer som PDE 2 inhibitorer | |
| WO2004087713A8 (en) | Salts of tricyclic inhibitors of poly(adp-ribose) polymerases | |
| NO20062398L (no) | Daglig, oral, kontrollert frigivnings oksycodon-doserings form | |
| WO2005004808A3 (en) | TETRACYCLIC COMPOUNDS AS c-MET INHIBITORS | |
| WO2002028860A3 (en) | Amino-substituted tetracyclic compounds useful as anti-inflammatory agents and pharmaceutical compositions comprising same | |
| GEP20105095B (en) | Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents | |
| WO2002070515A3 (en) | Chromane derivatives, process for their preparation and their use as antitumor agents | |
| BR0309996A (pt) | Composto, composição farmacêutica, método de tratar ou melhorar doenças ou condições proliferativas, uso de um composto, e, método de tratar ou melhorar doenças inflamatórias | |
| DE602004020063D1 (de) | Pyrido[2,3-d] pyrimidin-7-carbonsäurederivate, deren herstellung und deren verwendung als pharmazeutische mittel | |
| PH12012502122A1 (en) | Imidazo[1,2-a]pyridine derivative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |